Skip to content

Search

Showing results for "clinical trials"

Patient-reported outcome measures for paediatric acute lower respiratory infection studies

Patient-reported outcome measures (PROMs) are recommended for capturing meaningful outcomes in clinical trials. The use of PROMs for children with acute lower respiratory infections (ALRIs) has not been systematically reported. We aimed to identify and characterise patient-reported outcomes and PROMs used in paediatric ALRI studies and summarise their measurement properties.

Reducing the harm caused by radiation for children with brain cancer, including MRI evaluation of impacts of radiation therapy

Raelene Nick Endersby Gottardo BSc (Hons) PhD MBChB FRACP PhD Brainchild Fellow; Co-Head, Brain Tumour Research team Co-Head, Brain Tumour Research

Bacillus Cereus Bacteremia and Multiple Brain Abscesses During Acute Lymphoblastic Leukemia Induction Therapy

Bacillus cereus can cause serious infections in immunosuppressed patients. This population may be susceptible to B. cereus pneumonia, bacteremia, cellulitis,...

Dr Keely Bebbington awarded a JDRF fellowship

Congratulations to the Rio Tinto Children’s Diabetes Centre’s Dr Keely Bebbington on being awarded a JDRF Rebecca Davies Clinical Research Fellowship for her research that aims to prevent the onset of anxiety in children with T1D and their families.

Defining relevant hypoglycemia measures in children and adolescents with type 1 diabetes

As the choices of therapies in diabetes care multiply, it is essential to standardize the approach to measuring and recording hypoglycemia risk

Kings Birthday Honour for Children's Diabetes Centre Co-director

Congratulations to the Rio Tinto Children's Diabetes Centre Co-Director and Perth Children's Hospital Director of Research, Professor Timothy Jones, awarded a Member of the Order of Australia (AM) in the King's Birthday Honours List.

Invasive fungal disease and antifungal prophylaxis in children with acute leukaemia: a multicentre retrospective Australian cohort study

Invasive fungal disease is a common and important complication in children with acute myeloid leukaemia (AML). We describe the epidemiology of IFD in a large multicentre cohort of children with AML.

Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease

Invasive fungal disease (IFD) remains a challenging complication of treatment for paediatric acute leukaemia. Consensus fungal treatment guidelines recommend withholding chemotherapy to facilitate immune recovery in this setting, yet prolonged delays in leukaemia therapy increase risk of relapse.